President and CEO David Zaccardelli of Verona Pharma PLC (VRNA, Financial) executed a sale of 514,152 shares of the company on October 22, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 14,736,552 shares of the company.
Verona Pharma PLC is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases. The company's focus is on products that are designed to meet the needs of patients with conditions such as chronic obstructive pulmonary disease and asthma.
Over the past year, the insider has sold a total of 1,514,152 shares and has not made any purchases. This recent transaction is part of a broader trend observed at Verona Pharma PLC, where there have been 9 insider sells and 3 insider buys over the past year.
Shares of Verona Pharma PLC were trading at $4.38 on the day of the transaction, giving the company a market cap of approximately $2.83 billion. This valuation reflects the company's position in the market and its potential for growth.
For more detailed information on the company's valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors are encouraged to visit the respective links.
This insider sale could be of interest to investors tracking insider behaviors and company performance, providing insights into the perspectives of high-level executives within Verona Pharma PLC.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
